Systemic corticosteroids account for approximately 1.30 million FAERS reports (any-role named) in the public openFDA extract (export dated June 8, 2026) — about 78.4 percent serious and 11.5 percent (150,346) with a fatal outcome — making this the largest single-class cut in our series, led by prednisone (369,757) and dexamethasone (286,660), with a clear 2020 reporting peak driven by dexamethasone use in severe COVID-19.
This article provides a class-level descriptive read of corticosteroid reporting in the FDA Adverse Event Reporting System (FAERS), written for pharmacovigilance, medical-affairs, bone/oncology market-access, and payer teams who evaluate these numbers in formulary reviews, prior-authorization and reauthorization criteria, risk-management planning, and clinical guidelines. Every figure here is computed from the public openFDA FAERS extract (20,328,575 total reports, export dated June 8, 2026). It is not a disproportionality signal analysis, it is not a safety claim, and it is not incidence data. FAERS is a spontaneous-reporting system: it captures what was reported, never what was caused, and it has no exposure denominator. For the class-wide FAERS methodology and the database aggregate picture, see the companion analysis of 20 million FAERS reports and the FAERS report-reading workflow; for adjacent class cuts, see bisphosphonate FAERS analysis, JAK inhibitors, and opioid FAERS reporting profile in FAERS.
Methodology, in one paragraph
A report is counted for the class when a corticosteroid substance name appears anywhere in that report's drug list — as a suspect, concomitant, or interacting drug — using a substring match across the drug_substances, drug_generics, and drug_brands fields (so "prednisone" and "dexamethasone sodium phosphate" both count). Because a single report can name several drugs, the per-molecule totals sum to more than the 1,301,871 class-level (union, deduplicated) reports. A "serious" report is any report the FDA coded as serious. A report counts toward death when the seriousness field carries a death flag or the outcome field carries a Fatal outcome. Reactions are coded to MedDRA Preferred Terms and case-normalized. FAERS does not link a reaction to a specific drug within a multi-drug report, so the reaction counts below are report-level for reports that name a corticosteroid — they are not proof that the corticosteroid caused the event. This "any role" convention is intentionally inclusive and matches the other class cuts in this series; it will exceed suspect-only counts cited elsewhere.
How big is the corticosteroid adverse-event footprint in FAERS?
The corticosteroid class represents one of the largest clinical footprints in the history of the FDA Adverse Event Reporting System. Across all reporting years, the deduplicated union of reports naming at least one corticosteroid drug is 1,301,871.
To put this in perspective, this class cut is several times larger than other widely used classes in our pharmacovigilance series. For instance, our bisphosphonate FAERS analysis identified 191,890 reports — a class with a comparable decades-long market presence — and the opioid FAERS reporting profile is one of the most heavily litigated class cuts in the series. At 1.3 million reports, the corticosteroid footprint is several times larger than either, reflecting the ubiquitous nature of these agents across clinical medicine. Rather than signaling an unusually high hazard rate, the 1.3-million-report footprint is a direct indicator of exposure: corticosteroids are the therapeutic backbone for oncology regimens, severe autoimmune diseases, respiratory crises, and transplantation protocols worldwide.
The outcome distribution within this cohort highlights the high-acuity population receiving these therapies:
| Measure | Value | Share of Class |
|---|---|---|
| Total reports (any role) | 1,301,871 | 100.0% |
| Serious | 1,020,779 | 78.4% |
| Death flag or fatal outcome | 150,346 | 11.5% |
| Female patients | 647,117 | 49.7% |
| Male patients | 509,733 | 39.2% |
| Unknown patient sex | 145,021 | 11.1% |
The 78.4 percent seriousness rate and 11.5 percent mortality share must be interpreted through a clinical lens. Corticosteroids are frequently prescribed to patients facing severe, life-threatening pathologies, such as advanced hematologic malignancies (where corticosteroids act as direct lympholytic agents) or acute respiratory distress syndrome. In these contexts, hospitalization and mortality are common baseline events, and the reporting of an adverse event is highly likely to carry a serious or fatal designation due to the patient's underlying clinical status rather than drug toxicity.
The reporter mix within the corticosteroid dataset shows a strong professional bias, which contrasts sharply with consumer-driven or litigation-heavy drug classes:
| Reporter Type | Reports | Share of Class |
|---|---|---|
| Other healthcare professionals | 415,850 | 31.9% |
| Physicians | 401,045 | 30.8% |
| Consumers | 345,437 | 26.5% |
| Pharmacists | 85,921 | 6.6% |
| Unknown reporters | 48,595 | 3.7% |
| Lawyers | 5,023 | 0.4% |
With physicians and other healthcare professionals accounting for over 60 percent of all submissions, the corticosteroid safety profile in FAERS is predominantly a clinical-grade dataset. Lawyer-filed reports represent a negligible 0.4 percent (5,023 reports). This is a stark departure from litigation-heavy classes like opioids, where legal professionals submit a large portion of reports. It indicates that the corticosteroid registry represents spontaneous, clinical-use pharmacovigilance rather than legal positioning.
From a geographic standpoint, the United States leads the reporting countries, followed by Canada and the United Kingdom:
| Country | Reports | Share of Class |
|---|---|---|
| United States (us) | 499,409 | 38.4% |
| Unknown / Not Recorded | 229,620 | 17.6% |
| Canada (ca) | 152,201 | 11.7% |
| United Kingdom (gb) | 54,526 | 4.2% |
| Japan (jp) | 51,726 | 4.0% |
| France (fr) | 49,847 | 3.8% |
| Germany (de) | 37,434 | 2.9% |
| China (cn) | 22,173 | 1.7% |
Which corticosteroids drive the reporting volume?
The corticosteroid class consists of molecules with varied anti-inflammatory potencies, mineralocorticoid activities, routes of administration, and clinical indications. The reporting volume in FAERS is concentrated among a few flagship agents:
| Corticosteroid Substance | Reports (any role) | Primary Clinical Role |
|---|---|---|
| Prednisone | 369,757 | Systemic oral backbone for rheumatology and autoimmune diseases |
| Dexamethasone | 286,660 | High-potency oncology and acute respiratory distress therapy |
| Budesonide | 159,211 | Locally active inhaled (asthma/COPD) and oral (IBD) agent |
| Prednisolone | 152,925 | Active metabolite of prednisone, widely used in pediatrics and liquid formulations |
| Methylprednisolone sodium succinate | 116,219 | High-dose intravenous therapy for acute flares and transplant rejection |
| Methylprednisolone | 99,289 | Oral and local injectable formulations for moderate inflammation |
| Hydrocortisone | 89,879 | Physiologic replacement for adrenal insufficiency and acute critical illness |
| Hydrocortisone acetate | 55,837 | Topical and local anti-inflammatory applications |
| Triamcinolone acetonide | 18,324 | Local intra-articular injections and dermatologic applications |
| Cortisone acetate | 6,683 | Historically used physiologic glucocorticoid |
| Deflazacort | 6,245 | Specialty glucocorticoid primarily used in Duchenne muscular dystrophy |
Prednisone leads the class with 369,757 reports. This dominance is a direct reflection of its position as the default oral glucocorticoid for chronic inflammatory and autoimmune conditions, such as rheumatoid arthritis, lupus, and polymyalgia rheumatica. Dexamethasone sits second with 286,660 reports, reflecting its role as a high-potency agent (about six to seven times more potent than prednisone) with minimal mineralocorticoid activity, making it ideal for managing cerebral edema, chemotherapy-induced nausea, and myeloma regimens.
Methylprednisolone sodium succinate (116,219 reports) represents the intravenous powerhouse of the class, commonly deployed in high-dose pulse regimens (such as 500 mg to 1,000 mg daily for 3 to 5 days) to halt acute, severe organ-threatening inflammatory flares, multiple sclerosis relapses, or acute transplant rejection. Deflazacort (6,245 reports) is a newer addition to the class, approved in 2017 as a specialty glucocorticoid with a modified structure designed to optimize the therapeutic index, particularly for long-term use in patients with Duchenne muscular dystrophy.
It is critical to note a key database limitation regarding substances like budesonide (159,211 reports) and hydrocortisone acetate (55,837 reports). FAERS is substance-level, not route-level. Budesonide reports include inhaled formulations for asthma/COPD alongside oral formulations for Crohn's disease and ulcerative colitis. In pharmacovigilance, these local exposures are aggregated under the substance name, meaning local and systemic risks are blended in the raw counts. Access and medical-affairs teams must review these entries with route-of-administration filters to separate systemic glucocorticoid side effects from local mucosal or pulmonary events.
What does the 2020 reporting spike tell us about dexamethasone?
Reviewing the reporting trajectory by receive year reveals a stable baseline interrupted by a massive, statistically significant surge in 2020:
| Receive Year | Total Corticosteroid Reports |
|---|---|
| 2017 | 73,683 |
| 2018 | 91,925 |
| 2019 | 99,228 |
| 2020 | 108,928 |
| 2021 | 105,391 |
| 2022 | 101,195 |
| 2023 | 99,834 |
| 2024 | 97,480 |
| 2025 | 92,891 |
Corticosteroid reporting rose from 73,683 in 2017 to a historic peak of 108,928 in 2020. It remained elevated at 105,391 in 2021 before settling back into a mature generic range of 92,000–99,000 reports per year.
The 2020 surge is the single clearest pandemic signal in the FAERS database, driven almost entirely by the rapid clinical adoption of dexamethasone for severe COVID-19. In June 2020, the RECOVERY Collaborative Group trial demonstrated that dexamethasone (6 mg once daily, orally or intravenously, for up to 10 days) reduced 28-day mortality by one-third in patients receiving invasive mechanical ventilation and by one-fifth in patients receiving oxygen without invasive ventilation.
Following this readout, dexamethasone became the global standard clinical recommendation for hospitalized, oxygen-dependent COVID-19 patients. This massive expansion of exposure occurred in highly unstable, high-acuity ICU patients. The resulting FAERS data reflect this clinical shift, with a high concentration of reports documenting respiratory failure, secondary pneumonia, and death in patients receiving dexamethasone as part of their COVID-19 treatment.
Biochemically, a 6 mg dose of dexamethasone is equivalent to approximately 40 mg of prednisone or 160 mg of hydrocortisone, representing a profound supra-physiological dose that completely suppresses the endogenous hypothalamic-pituitary-adrenal (HPA) axis. In the context of severe systemic viral infection, this pharmacologic suppression of the immune system represents a delicate balance: while it prevents the lethal inflammatory cascade ("cytokine storm"), it simultaneously compromises local host defenses, predisposing patients to secondary bacterial pneumonia and fungal infections. This historical event demonstrates why FAERS volumes must be interpreted as exposure-weighted rather than hazard-weighted: a sudden spike in reports is often the result of a rapid change in clinical practice guidelines rather than a newly discovered drug toxicity.
What are the most-reported reactions and outcomes?
In an "any role" class analysis, the raw list of adverse reactions is a combination of true drug-induced adverse events, the complications of the underlying diseases being treated, and the side effects of concomitant therapies:
| Reaction (MedDRA Preferred Term) | Reports | Clinical / Epidemiologic Context |
|---|---|---|
| Drug ineffective | 109,599 | Reflects underlying disease progression or treatment failure |
| Off label use | 101,392 | Frequent in oncology, rare diseases, and early pandemic protocols |
| Dyspnoea | 70,217 | Common baseline symptom in severe asthma, COPD, and COVID-19 |
| Fatigue | 62,909 | Non-specific systemic symptom common across oncology and autoimmune diseases |
| Diarrhoea | 55,958 | Multifactorial; often driven by concomitant chemotherapies or antibiotics |
| Nausea | 44,995 | Highly correlated with concomitant chemotherapy or baseline illness |
| Pneumonia | 43,378 | Immunosuppression risk factor associated with high-dose glucocorticoids |
| Arthralgia | 42,780 | Underlying rheumatologic disease or steroid-withdrawal syndrome |
| Condition aggravated | 42,468 | Progression of baseline oncology or autoimmune conditions |
| Death | 39,197 | High-acuity patient baseline mortality |
The presence of "drug ineffective" (109,599 reports) and "off label use" (101,392 reports) at the top of the list highlights the administrative and clinical complexity of these patients. Corticosteroids are frequently used off-label in oncology and rare-disease regimens before formal labeling is updated.
The pharmacologic mechanism of corticosteroids explains much of this reporting profile. Corticosteroids diffuse across cell membranes and bind to the cytosolic glucocorticoid receptor (GR). The ligand-receptor complex then translocates to the nucleus, where it acts via two primary pathways: transactivation (binding to glucocorticoid response elements on DNA to upregulate anti-inflammatory proteins) and transrepression (binding to and inhibiting pro-inflammatory transcription factors like NF-kB and AP-1). While transrepression is the primary driver of therapeutic anti-inflammatory efficacy, transactivation leads to the upregulation of genes involved in gluconeogenesis, lipolysis, and protein catabolism, resulting in the classic adverse effect profile (hyperglycemia, osteoporosis, muscle wasting, and impaired wound healing).
The suppression of macrophage phagocytosis and cytokine production (specifically IL-1, IL-6, and TNF-alpha) decreases the patient's ability to clear pathogens. This biological mechanism directly correlates with the high volume of pneumonia (43,378 reports) in the FAERS database. Furthermore, corticosteroids impair osteoblast function and promote osteoclast survival, driving the rapid onset of bone loss. In patients receiving long-term treatment, this leads to fragility fractures, which often present in FAERS under terms like arthralgia or pain.
The outcome distribution for matched reports shows the severe baseline clinical status of this cohort:
| Outcome Category | Reports | Share of Class |
|---|---|---|
| Unknown / Not Reported | 685,461 | 52.7% |
| Recovered | 322,996 | 24.8% |
| Not Recovered | 238,836 | 18.3% |
| Recovering | 150,626 | 11.6% |
| Fatal | 117,741 | 9.0% |
| Recovered with Sequelae | 12,496 | 1.0% |
The 9.0 percent explicit "fatal" outcome rate (representing 117,741 reports, while the broader death flag identifies 150,346 reports when including the seriousness field) reflects the high-risk specialties where systemic corticosteroids are used, particularly oncology and critical care.
How does corticosteroid reporting compare to other drug classes?
The corticosteroid reporting profile in FAERS stands in sharp contrast to other major drug classes in our series:
- Litigation Profile: While classes like opioids and bisphosphonates are heavily shaped by legal reporting (with opioids showing significant lawyer-driven volume), corticosteroids show a negligible lawyer-report share of 0.4 percent. This signals that the database is free of litigation-driven spikes and reflects ongoing clinical-use surveillance.
- Acuity and Seriousness: The 78.4 percent seriousness rate of corticosteroids exceeds that of more routine chronic classes, such as statins or proton-pump inhibitors, which average lower seriousness rates. This difference is driven by the indication mix: corticosteroids are therapeutic backbones for severe, acute, or advanced disease states, whereas statins are used for outpatient primary and secondary cardiovascular prevention.
- COVID-19 Pandemic Footprint: Unlike any other class in our series, the corticosteroid trajectory carries a prominent peak in 2020. This unique footprint is a historical record of the global mobilization of dexamethasone following the RECOVERY trial, providing a clear demonstration of how clinical trials reshape real-world safety database patterns.
What are FAERS's limitations for interpreting corticosteroid safety?
While the 1.3-million-report footprint provides a deep reservoir of real-world data, users must apply several analytical guardrails to avoid misinterpreting the signals:
- No Exposure Denominator: FAERS cannot be used to calculate the absolute incidence of side effects. Because we do not know the total number of patients taking corticosteroids (the denominator), we cannot determine if prednisone is safer than dexamethasone based on report volume alone.
- Reporting Bias and Underreporting: Spontaneous reporting systems are subject to Weber-effect dynamics (higher reporting immediately post-launch) and selective reporting of severe events. Long-established generic drugs like prednisone are subject to chronic underreporting for known side effects (such as osteoporosis, hyperglycemia, or weight gain) because clinicians do not feel the need to report well-known, predictable class reactions.
- Concomitant Drug Confounding: Since corticosteroids are rarely used in isolation, particularly in oncology and rheumatology, separating the safety signal of the steroid from concomitant biologics, chemotherapies, or immunosuppressants is extremely difficult. The any-role convention captures the entire therapeutic ecosystem, not just the single drug's direct toxicities.
What this means for pharmacovigilance, medical-affairs, and access teams
- Disambiguate the Substance-Level Budesonide and Betamethasone Data: Budesonide (159,211 reports) and betamethasone dipropionate (9,283 reports) represent a blend of inhaled, oral, and topical formulations. Access teams must apply route-of-administration filters before citing these figures in safety dossiers or prior-authorization criteria.
- Recognize the Indication-Driven Outcome Bias: The 11.5 percent death-flag rate is concentrated in the oncology (plasma cell myeloma, 141,902 reports) and ICU cohorts. Do not present these figures as general steroid toxicity parameters to patients or clinicians in lower-risk outpatient settings, such as mild asthma or localized dermatologic care.
- Interpret Trajectory Spikes as Exposure Shifts: The 2020 dexamethasone peak (108,928 reports) is an indicator of rapid clinical guideline adoption (RECOVERY trial) in a highly vulnerable patient population, illustrating that database surges frequently reflect therapeutic utility and volume rather than a safety failure.
- Build Structured Patient-Monitoring Protocols for High-Dose Therapy: Since high-dose IV methylprednisolone (116,219 reports) is associated with acute cardiovascular and metabolic events (including severe hypertension, cardiac arrhythmias, and acute hyperglycemia), clinical guidelines and patient-assistance programs should integrate mandatory clinical monitoring (blood pressure, electrocardiograms, and blood glucose checks) into their care pathways.
- Mitigate Glucocorticoid-Induced Osteoporosis (GIOP) Early: Because skeletal fragility is a cumulative class effect, clinical guidelines should require the concurrent prescription of bone-protective therapies (such as bisphosphonates) at the time chronic systemic corticosteroids (defined as prednisone equivalent >= 2.5 mg/day for 3 months or longer) are initiated, rather than waiting for bone mineral density (BMD) T-scores to drop into the osteoporotic range.
FAQ
Does a high FAERS count mean corticosteroids are unsafe?
No. The 1.30-million-report footprint is primarily a function of massive global exposure over four decades. Because corticosteroids are used across nearly every medical specialty — from oncology and transplant to rheumatology and respiratory medicine — they accumulate a large reporting base. FAERS counts track utilization and patient acuity, not individual drug risk.
Why is dexamethasone reporting so concentrated in 2020?
Following the publication of the RECOVERY trial results in June 2020, which demonstrated a survival benefit for dexamethasone in severe COVID-19, the drug became the global standard clinical recommendation for hospitalized, oxygen-dependent patients. The sudden exposure of millions of high-acuity, ICU-level patients to dexamethasone led directly to the 2020 reporting surge.
Why are so many corticosteroid reports serious or fatal?
Corticosteroids are the therapeutic backbone for high-severity indications, such as plasma cell myeloma (141,902 reports) and severe autoimmune conditions. The 78.4 percent seriousness rate and 11.5 percent death-flag rate are population effects: the patients receiving systemic corticosteroids are often critically ill, and their baseline risk of hospitalization or death is high due to their underlying diagnoses.
Can we separate systemic and local corticosteroid reports in FAERS?
The raw openFDA FAERS database is substance-level, meaning budesonide (159,211 reports) combines inhaled asthma therapies with oral Crohn's disease treatments. To separate these signals, pharmacovigilance teams must run custom queries that parse the route-of-administration field within the individual case reports.
Sources
- US FDA, openFDA FAERS (Adverse Event Reporting System) extract, export dated June 8, 2026. Class-union, per-molecule, outcome, reaction, indication, and trajectory aggregates computed by PharmaDossier from the public FAERS extract using an any-role substring match across drug substance, generic, and brand fields. https://open.fda.gov/data/faers/
- RECOVERY Collaborative Group. "Dexamethasone in Hospitalized Patients with Covid-19." New England Journal of Medicine 2021;384(8):693-704 — clinical basis for the 2020 dexamethasone-use surge in severe respiratory illness. https://pubmed.ncbi.nlm.nih.gov/32678530/
- US FDA, Center for Drug Evaluation and Research (CDER). Drugs@FDA database for systemic and topical corticosteroid approvals, labeling updates, and safety communications. https://www.accessdata.fda.gov/scripts/cder/daf/
- Ophthalmic corticosteroids FAERS safety profile disproportionality framing and class-level reporting reference. Frontiers in Pharmacology 2024;15:1502047. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1502047/full
- Hydrocortisone-specific adverse-event disproportionality reporting and database characteristics. QXMD Read / PubMed PMID 40163037. https://pubmed.ncbi.nlm.nih.gov/40163037/
